Carisma Therapeutics Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
License and related revenue
Total revenue

Collaboration revenues
Operating expenses:
Research and development
General and administrative
Restructuring charge
Intangibles impairment charge
Change in fair value of contingent consideration
Total operating expenses
Operating loss
Interest income
Other income (expense), net
Loss Before Taxes
Benefit (provision) from income taxes
Change in fair value of derivative liability
Interest income, net
Net loss
Deemed Dividend
Net loss and comprehensive loss attributable to common shareholders
Net loss per common share - basic and diluted (in dollars per share)
Weighted-average common shares outstanding - basic and diluted (in shares)
Net loss attributable to common stockholders - basic
Unrealized gain on marketable securities
Less: reclassification to net loss of previous unrealized gain on marketable securities
Comprehensive loss
Share information:
Net loss per share of common stock, basic (in USD per share)
Net loss per share of common stock, diluted (in USD per share)
Weighted-average shares of common stock outstanding, basic (in shares)
Weighted-average shares of common stock outstanding, diluted (in shares)

Comments